2nd Annual MarketsandMarkets

Real-World Data and Life Science Analytics Congress

October 24 - 25, 2019

DoubleTree by Hilton Boston-Downtown

5+

Sessions

20+

Speakers

100+

Attendees

10+

Networking Hours

The next step towards utilizing Real-World Evidence to drive Life Science and Healthcare Innovation

With the increasing recognition of real-world data opportunities and challenges within the pharmaceutical and biotech industry, life sciences organizations face clear decisions on how specifically to put resources into real-world evidence capacities. Real-World Evidence can possibly change the way life sciences associations use advancements to increase further clinical bits of knowledge and enable them and payers to collaborate like never before. After the successful inaugural, this year’s congress will hold discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation.

Tag Line
Learn how adoption of real-world evidence can be accelerated across pharmaceutical industry
Tag Line
Explore capabilities of using Artificial Intelligence & Machine Learning in taming scientific research
Tag Line
Understand the impact of innovative real-world evidence partnerships for better data

WHAT TO EXPECT

  • Adopting the Right Methodology for Real-World Evidence
  • Achieving New Level of Quality Insights from Data
  • Artificial Intelligence & Blockchain: Gamechanger in Real-World Evidence
  • Strategic Framework & Regulatory Considerations
  • Breakthrough to Excellent Data Evaluation

  • Real-World Evidence Methodologies
  • FDA’s new strategic framework for use of real-world evidence
  • Applications of AI & Blockchain for Real-World Data Analysis 
  • Evaluation of data sources for better patient outcomes
  • Accelerating adoption of RWE in the pharmaceutical industry and across

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, from Pharmaceutical and Biopharmaceutical companies working in the following departments- Real-World Evidence | Health Economics & Outcomes Research  | Market Access  | Value Access | Clinical Outcomes | Clinical Development 

CONFERENCE AGENDA

Registration

08:15 - 09:05

Welcome note from MarketsandMarkets

09:05 - 09:10

Opening Remarks from the Chairman

Charles Makin

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:10 - 09:15

STRATEGIC FRAMEWORK & REGULATORY CONSIDERATIONS

Keynote Presentation: Real World Evidence - Beginning with a Considered Strategy for the Maximum Payoff

Charles Makin

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:15 - 09:45

FDA’s Real-World Evidence Program: Framework for Evaluating RWD/ RWE for Use in Regulatory Decisions

Nneka Onwudiwe

Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

09:45 - 10:15

Real-World derived Spatiotemporal Diagnosis Patterns as Descriptors for Patient Stratification and Design of Precision Medicine Solutions

Reena Gollapudy

Reena Gollapudy, Senior Director and Head, Health Outcomes BU, , Indegene

10:15 - 10:45

Morning Refreshments | One-to-One Networking Meetings | Networking break

10:45 - 11:35

Panel discussion: Pros & Cons of Real-World Evidence framework by FDA. Perspective from different stakeholders- providers & payers

11:35 - 12:15

Real-world evidence: How to improve your patient-centered strategy in Life Sciences?

George Mathew

George Mathew, Chief Medical Officer, Americas, DXC Technology

12:15 - 12:45

Economics of real-world data

Simon Dagenais

Simon Dagenais, Director, Global Center of Excellence in Real-World Evidence, Vertex Pharmaceuticals

12:45 - 13:15

Lunch | One-to-One Networking Meetings | Networking break

13:15 - 14:15

ACHIEVING NEW LEVEL OF QUALITY INSIGHTS FROM DATA

Treatments for Health Conditions with High Patient Heterogeneity: Can Real World Data Make Our Drug Development Programs Smarter?

Vic Spain

Vic Spain , Senior Real World Data Scientist , Genentech

14:15 - 14:45

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

David Thompson

David Thompson, Senior Vice President, Head Of Thought Leadership, Real-World And Late Phase Research, Syneos Health

14:45 - 15:15

Afternoon Refreshments | One-to-One Networking Meetings

15:15 - 16:10

Evaluating Strengths and Limitations of Real-World Data for Better Real-World Evidence Generation

Susan Fish

Susan Fish , Associate Director, Strategic Evidence Integration and Collaborations US Medical Affairs Hematology,, Bristol-Myers Squibb

16:10 - 16:40

Breakout Session

16:40 - 17:10

Closing remarks from the chairperson

17:10 - 17:15

Drinks Reception & Networking

17:15 - 18:15

LIFE SCIENCE ANALYTICS

Advancing Commercial Analytics through Real World Data

Rachel Twardowski

Rachel Twardowski, Director, IBD Business Insights, Takeda Pharmaceuticals

14:15 - 14:45

Putting the Patient into Patient Journey

Simon Andrews

Simon Andrews, Vice President, DRG Analytics, Decision Resources Group

14:45 - 15:15

Afternoon Refreshments | One-to-One Networking Meetings

15:15 - 16:10

Deriving value from Real World Data with Artificial Intelligence & Machine Learning

Jyotsna Kasturi

Jyotsna Kasturi , Associate Director, Real World Evidence Statistics, Teva Pharmaceuticals

16:10 - 16:40

Break out session

16:40 - 17:10

Closing remarks from the chairperson

17:10 - 17:15

Drinks Reception & Networking

17:15 - 18:15

Registration

08:15 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening Remarks from the Chairman

Charles Makin

Charles Makin , Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

09:00 - 09:10

ADOPTION OF THE RIGHT METHODOLOGY FOR REAL-WORLD EVIDENCE

Organizational Evolution of observational research in Pharma

David Miller

David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

09:10 - 09:45

Accelerating RWE through Novel Data and Site Network Access

Janak Joshi

Janak Joshi, SVP & Chief Technology Officer, LifeImage

09:45 - 10:15

Use case: Impact of innovative Real-World Evidence partnerships to get better data

Brian Sweet

Brian Sweet , Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb

10:15 - 10:45

Morning Refreshments | One-to-One Networking Meetings | Networking break

10:45 - 11:45

BREAKTHROUGH TO EXCELLENT DATA EVALUATION

Panel Discussion: Maximize the Influence of Real-World Evidence by Utilizing Available Data to Drive Life Science Innovation and Drug Development

11:45 - 12:30

Using Real World Data to Inform Early Disease Understanding

Yizhou Ye

Yizhou Ye, Epidemiologist, Takeda Pharmaceutical

12:30 - 13:00

Lunch | One-to-One Networking Meetings | Networking break

13:00 - 14:00

Demonstrating Real-World Reliability to Support Fitness-for-Use

Nirosha Lederer

Nirosha Lederer , Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University

14:00 - 14:30

Closing remarks from the Chairman

14:30 - 14:45

CONFERENCE SPEAKERS

ADVISORS

Charles Makin

Charles Makin

Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

Brian Sweet

Brian Sweet

Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb

SPEAKERS

Charles Makin

Charles Makin

Global Head of HEOR and RWE, Global Head of Pipeline Value & Access, Biogen

Brian Sweet

Brian Sweet

Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb

Susan Fish

Susan Fish

Associate Director, Strategic Evidence Integration and Collaborations US Medical Affairs Hematology,, Bristol-Myers Squibb

Jyotsna Kasturi

Jyotsna Kasturi

Associate Director, Real World Evidence Statistics, Teva Pharmaceuticals

Vic Spain

Vic Spain

Senior Real World Data Scientist , Genentech

Nirosha Lederer

Nirosha Lederer

Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University

Simon Andrews

Simon Andrews

Vice President, DRG Analytics, Decision Resources Group

David Thompson

David Thompson

Senior Vice President, Head Of Thought Leadership, Real-World And Late Phase Research, Syneos Health

Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

David Miller

David Miller

Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

Rachel Twardowski

Rachel Twardowski

Director, IBD Business Insights, Takeda Pharmaceuticals

Hannah Ebben

Hannah Ebben

Marketing Analytics Specialist, Takeda Pharmaceuticals

Kristen Coletto

Kristen Coletto

Senior Director, Product,, Aetion

Janak Joshi

Janak Joshi

SVP & Chief Technology Officer, LifeImage

Matthew A. Michela

Matthew A. Michela

President & CEO, LifeImage

Elodie Baumfeld Andre

Elodie Baumfeld Andre

Senior Director, Epidemiology Strategy Lead, Worldwide Medical & Safety, Pfizer

Fred Francis

Fred Francis

CEO, Imagia

Yizhou Ye

Yizhou Ye

Epidemiologist, Takeda Pharmaceutical

Reena Gollapudy

Reena Gollapudy

Senior Director and Head, Health Outcomes BU, , Indegene

Simon Dagenais

Simon Dagenais

Director, Global Center of Excellence in Real-World Evidence, Vertex Pharmaceuticals

Anand Shewale

Anand Shewale

Associate Director, Global Health Economics and Outcome Research, Allergan

George Mathew

George Mathew

Chief Medical Officer, Americas, DXC Technology

Sharad Khusal

Sharad Khusal

Account Executive, Dedalus Group

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

DoubleTree by Hilton Boston-Downtown

PAST EVENT GALLERY